SSG
RXII

Summit Securities Group’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Summit Securities Group’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-700
Closed -$2K – 721
2014
Q1 		$2K Buy
+700
New +$2K ﹤0.01% 356

Other funds holding RXII

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $2.46B AUM 57.16% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Summit Securities Group's RXII Position: Q2 2014 in Review

Summit Securities Group sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2014, closing a stake of 700 shares — an estimated $2K sold.

Summit Securities Group first reported a position in RXII in Q1 2014 and held it in 1 quarter. The position peaked at $2K in Q1 2014. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2014.

  • Summit Securities Group reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2014 after selling out during the quarter.
  • Summit Securities Group sold 700 GALENA BIOPHARMA INC COM shares in Q2 2014, an estimated $2K.
  • Summit Securities Group first reported a position in GALENA BIOPHARMA INC COM in Q1 2014 and held it in 1 quarter.
  • Summit Securities Group's GALENA BIOPHARMA INC COM position peaked at $2K in Q1 2014.
  • 90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2014.

Based on Summit Securities Group's 13F filing for Q2 2014, filed 12 Aug 2014.